S1052: Better Empowerment Now to Enhance Framework and Improve Treatments Act of 2017

By | February 20, 2018
FDA logo

Food and Drug Administration logo.

Requires the FDA to consider patient-focused data, such as patient-reported outcomes, in its risk-benefit assessment of new drugs.

Official Summary

Better Empowerment Now to Enhance Framework and Improve Treatments Act of 2017 or the BENEFIT Act of 2017

This bill amends the Federal Food, Drug, and Cosmetic Act to require the Food and Drug Administration (FDA) to consider patient-focused drug development data, such as patient preferences, patient-reported outcomes, and patient experiences, as part of the risk-benefit assessment of new drugs. Following approval of a drug, the FDA must include a description of how this information was considered in its statement of patient experience.

Passed House
Passed Senate
2017-08-03
Signed by President
Became Public Law

Amendments

None.

Sponsors

Original sponsor: Sen. Wicker, Roger F. [R-MS]

Cosponsors: Sen. Klobuchar, Amy [D-MN]

Votes

Passed Senate by unanimous consent.

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.